Age and Insulin Resistance

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-80
SponsorUniversity of Lausanne

About this trial

Insulin resistance is a crucial factor for the development of type 2 diabetes and a major health problem for older adults. It is the principal mechanism by which obesity is considered to increase the risk for type 2 diabetes and is a key feature of the metabolic syndrome. The elevated prevalence of obesity and type 2 diabetes in the older population has important consequences on the morbidity and mortality as well as on the economic burden on society. Controversy currently exists as to whether or not aging contributes to insulin resistance. Many potential factors confound the association between aging and insulin resistance, including obesity and physical inactivity.

Ectopic lipid depositions, defined as an excess accumulation of triglycerides in non adipose tissues such as in the liver (intrahepatic lipids) and within the muscle fibers (intramyocellular lipids), are positively associated with obesity and insulin resistance. Furthermore, the accumulation of intracellular lipids is often cited as being a key determinant in the underlying mechanisms of insulin resistance. In addition of playing an important role in obesity and type 2 diabetes, these ectopic fat depositions are also observed in common conditions such as aging and physical inactivity.

The intervention trial will test in skeletal muscle, liver and heart of sedentary obese volunteers, normal weight volunteers and masters athletes, the overall hypotheses that exercise improvement of fat oxidation capacity and/or decrease of damaging fat metabolites is a primary factor that predicts the improvement in insulin resistance.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 60-80

Sedentary or highly trained

BMI 18-40

Non-Smoker

Disqualifiers

Contraindication to moderate exercise or clinical conditions precluding from joining an exercise program, such as clinically significant cardiovascular disease, peripheral vascular disease, uncontrolled hypertension, neurological or orthopedic disease

Recent weight loss or weight gain

Known diabetes

Known drugs to affect glucose homeostasis such as nicotinic acid, glucocorticoids

Trial design

Design model

Parallel

Treatments tested in this trial

  • Physical activity

    Behavioral

    Supervised exercise intervention

Treatment groups

150 Participants
are divided into 3 treatment groups
Group A: Sedentary obeseExperimental treatment 1 intervention
Group B: Sedentary normal weightExperimental treatment 1 intervention
Group C: AthletesNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Insulin sensitivity

Time frame
0-4 months
2

Ectopic lipids

Time frame
0-4 months
3

Oxidative capacity

Time frame
0-4 months

Secondary outcomes

1

Body composition

Time frame
0-4 months
2

Metabolic flexibility

Time frame
0-4 months
3

Exercise efficiency

Time frame
0-4 months
4

Physical fitness

Time frame
0-4 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Lausanne

Lead sponsor

Centre Hospitalier Universitaire Vaudois

Collaborator